ABOUT US

We create new proprietary plant genetics by breeding strains that are rich in certain cannabinoids, which we then isolate and use in biomedical research to ultimately create health supplements and medication.

GHM Genetic Development is an international pioneer in the breeding of new plant varieties for therapeutic extracts.

Our Services

We offer consulting, sourcing, biomedical r&d, licensing and production services for legally-authorized distributors, producers, processors, formulators and licensed regulators.

Biomedical Research & Consulting

We isolate cannabinoids, which we then use in biomedical research to ultimately create health supplements and medication. We research the therapeutic properties and health benefits of isolated cannabinoids, and how they can be used optimally to treat and prevent diseases. One of our major aims is to reduce the psychoactive properties and thus optimize the therapeutic potential of our extracts. With our governmental, academic and clinical partners we are preparing to run large-scale clinical research in the Democratic Republic of Congo.
Cultivation Technology & Design Consulting

We provide cultivators/producers & regulators consulting on all the aspects of the growing process from cultivation design, the harvest processing to harmful/dangerous waste management. GHM uses the most recent methods and cutting edge technology, with our team’s over 35 years of experience, we provide services that can help create successful cultivation facilities with crops that generate the highest yields with lowest overhead costs.
Licensing & Development of Proprietary Strains

We create new plant genetics by breeding strains with specific cannabinoid- and terpene profiles. Our proprietary genetics are also available for third-party licensing. Officially licensed GHM strains are bred and processed according to Good Agricultural Collection Practices for Medicinal Plants and are fully traceable. GHM proprietary genetics are promoted through our marketing channels.
Cultivation & Production of Certified and non-Certified Raw Materials

With our partner Green House DRC, we are licensed to produce and export raw plant material and crude cannabinoid extracts on an industrial scale in equatorial Africa.

Our raw materials and extracts come with all the necessary documentation and certification and are available for refinement, research and product formulation by pharmaceutical and academic partners.

One of our major aims is to reduce the psychoactive properties and optimize the therapeutic potential of our extracts by:

Cultivating varieties that are high in other cannabinoids than THC and producing new therapeutic cultivars by back crossing with existing strains
Shielding the psychoactive properties of THC by mixing with other non-psychoactive cannabinoids
Preventing the conversion of non-psychoactive THCA to THC by exploration of cold-extraction techniques

Our Vision

GHM Genetic Development aims to isolate the active ingredients in medicinal plant extracts and tests their therapeutic potential both individually and in combination.

Our primary goal is to isolate plant-derived modulators of the endocannabinoid system (ECS). The ECS performs a critical role in maintaining physiological balance, promoting physical health and preventing disease.

An increasing number of seemingly distinct diseases are now recognized as deficiencies of the ECS. ECS modulators can therefore be used to restore balance in the ECS and to prevent or treat diseases.

To date, we have evidence for the therapeutic potential of ECS modulators in over 50 diseases including major pubic health threats such as cancer, Alzheimer’s disease, obesity, diabetes, epilepsy, Parkinson’s disease and depression.

Once we have identified the optimal formulation for any particular disease, we intend to breed new varieties, which confer these specific genetic traits.

We have access to one of the world’s largest genetic libraries of medicinal plant varieties. Our library includes several unique landraces, which were obtained by the Strain Hunters on expeditions to the most remote regions of the world and will serve as a starting point for further genetic development.

Our Team

Who’s behind the scenes?

Heiko Hampsink

Chief Executive Officer

Heiko has been active in international business development for 2 decades. Inspired by the therapeutic potential of cannabinoids, Heiko founded GHM in 2014 as a research vehicle under Stichting Strain Hunters Foundation.

Alberto Sainz

Science Manager

Alberto designs and runs scientific studies about the potential therapeutic effects of cannabis for GHM. He has a BSc in Psychology and an MSc in Neurobiology.

Joan Espel Grekopoulos

Research Scientist, Biochemistry

Joan is a multidisciplinary scientist in fields like biochemistry and biophysics, both from an experimental as well as from a theoretical point of view.

18ENDOCANNABINOIDS

32PLANT CANNABINOIDS

42CANNABINOID RECEPTORS

1000SOLUTIONS

Milestones

Brief History of Events Leading to the Formation of GHM Genetic Development

December 2007

In 2007 the Strain Hunters Foundation also known as the Green House social outreach program is initiated, with the purpose of supporting communities in the poorest regions in the world, where Strain Hunters documentaries are produced.

October 2014

Stichting Strain Hunters Foundation is registered in the Chamber of Commerce of The Netherlands and GH Medical starts researching therapeutic cannabinoids and how they can be used to help prevent and treat diseases.

November 2016

Stichting Strain Hunters Foundation, GHM Europe, and Green House DRC collaborate and obtain the first production, research and distribution license in the Democratic Republic of Congo.

May 2017

GHM Europe B.V. is formed in the Netherlands and takes over research activities of GH Medical from the Stichting Strain Hunters Foundation and starts commercial activities.

August 2017

GHM Europe B.V. launches a subsidiary in Spain GHM Genetic Development, SL to ultimately create new proprietary plant genetics by breeding strains that are rich in certain cannabinoids, which we then isolate and use in biomedical research to ultimately create health supplements and medication.

What we do